Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03733132 · ClinicalTrials.gov registry record · Phase 2
Metformin Effect on Brain Function in Insulin Resistant Elderly People
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT03733132: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT03733132 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03733132, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
Alzheimer's disease (AD) and other forms of dementia are rapidly increasing with the aging of the population, and show a clear preponderance among people with insulin resistance. Metformin, an insulin sensitizer, is being examined in clinical trials as an anti-aging drug. However, very little objective data is available regarding metformin's effect on the brain, a major organ affected by aging.
Interventions
- DRUG Metformin Hydrochloride
- DRUG Placebo Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2019-03-15 |
| Est. Completion | 2023-04-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03733132
The ClinicalTrials.gov registry entry for NCT03733132 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Metformin Hydrochloride is the first listed.
NCT03733132 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03733132 about?
NCT03733132 is a clinical study titled "Metformin Effect on Brain Function in Insulin Resistant Elderly People". Alzheimer's disease (AD) and other forms of dementia are rapidly increasing with the aging of the population, and show a clear preponderance among people with insulin resistance. Metformin, an insulin sensitizer, is being examined in clinical trials as an anti-aging drug. However, very little object...
What is the current status of trial NCT03733132?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2019-03-15. Estimated completion is 2023-04-05.
What interventions are being tested in trial NCT03733132?
The interventions under investigation include: Metformin Hydrochloride (DRUG), Placebo Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT03733132?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.